BIO3 Share Price

Open 21.90 Change Price %
High 21.99 1 Day -0.27 -1.22
Low 21.52 1 Week -1.80 -7.63
Close 21.80 1 Month 2.04 10.32
Volume 75145 1 Year 7.99 57.86
52 Week High 23.88
52 Week Low 12.02
BIO3 Important Levels
Resistance 2 22.24
Resistance 1 22.06
Pivot 21.77
Support 1 21.54
Support 2 21.36
ETR Germany Most Active Stocks
DBK 15.04 -1.05%
DBK 15.04 -1.05%
EOAN 9.03 -0.22%
EOAN 9.03 -0.22%
CBK 9.30 -0.64%
CBK 9.30 -0.64%
DTE 16.70 -0.48%
DTE 16.70 -0.48%
DTE 16.70 -0.48%
DTE 16.70 -0.48%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
NK2A 0.09 28.57%
TLI 0.18 20.00%
TLI 0.18 20.00%
F2Y 27.50 14.11%
5M71 39.00 13.70%
R3Q 0.11 10.00%
ULC 2.55 9.91%
S3F 58.85 9.51%
E8X 0.60 9.09%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
ZSB 0.10 -16.67%
MWB 4.20 -9.09%
DTD2 5.34 -7.93%
ZEF 1.18 -7.81%
FOH 1.45 -7.05%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 4
As on 22nd Jun 2017 BIO3 Share Price closed @ 21.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.84 & Buy for SHORT-TERM with Stoploss of 20.31 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for June
1st Target up-side 22.98
2nd Target up-side 24.19
3rd Target up-side 25.4
1st Target down-side 19.52
2nd Target down-side 18.31
3rd Target down-side 17.1
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.